F-1/A: Polyrizon Ltd. Files for IPO to Advance Nasal Spray Technologies

Polyrizon Ltd. aims to raise capital through an IPO to further develop its innovative medical device hydrogels delivered as nasal sprays for protection against viruses and allergens.

Summary

• Polyrizon Ltd., a development stage biotech company, has filed a registration statement for an IPO to fund the development of its nasal spray technologies.
• The company's primary focus is on its Capture and Contain (C&C) hydrogel technology, designed to act as a barrier against viruses and allergens in the nasal cavity.
• Polyrizon is also developing Trap and Target (T&T) technology for nasal delivery of active pharmaceutical ingredients.
• The IPO includes an offering of 865,385 units, each consisting of one ordinary share and three warrants, with an anticipated price range of $4.20 to $6.20 per unit.
• Pre-funded units are also being offered as an alternative for investors with ownership limitations.
• The company intends to list its Ordinary Shares on The Nasdaq Capital Market under the symbol PLRZ.
• Polyrizon plans to use the net proceeds to advance its PL-14, PL-15, and PL-16 product candidates, complete in vitro feasibility studies for its T&T platform, repay convertible loans, and for general corporate purposes.
• The company has granted the underwriter an option to purchase additional Ordinary Shares and/or Warrants and/or Pre-Funded Warrants to cover over-allotments.
• The company has entered into a license agreement with SciSparc, issuing Ordinary Shares and warrants in exchange for exclusive rights to the SCI-160 platform for pain treatment.
• The company has signed a collaboration agreement with NurExone Biologic Inc. to develop formulations for intranasal delivery of NurExones ExoTherapy for spinal cord injuries.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of the company's technologies and the risks associated with its business. The sentiment is neutral, reflecting the inherent uncertainties in the biotech industry.

Positives

• The company has a clear plan for using the IPO proceeds to advance its product candidates.
• The company has established collaborations with SciSparc and NurExone, which could provide additional revenue streams and development opportunities.
• The company is targeting large and growing markets with its nasal spray technologies.
• The company has a management team with extensive experience in the life sciences industry.

Negatives

• The company has a history of net losses and expects to continue incurring losses for the foreseeable future.
• The company will need to raise substantial additional funding to continue its operations.
• The company's product candidates are subject to regulatory approval, which is a lengthy and uncertain process.
• The company faces intense competition in the pharmaceutical and medical device industries.
• The company's success depends on the market acceptance of its product candidates, which is uncertain.

Risks

• The company has incurred significant losses since its inception and may never be profitable.
• The company depends on enrollment of patients in its upcoming clinical trials in order to continue development of its product candidates.
• The company may not receive, or may be delayed in receiving, the necessary clearances or approvals for its product candidates.
• The company is heavily dependent on the success of its C&C product candidates.
• The company faces intense competition in an environment of rapid technological change.
• The company relies on third parties to manufacture the raw materials that it uses to create its product candidates.
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israels war against them.

Future Outlook

The company expects expenses and operating losses to increase as it continues clinical development of its product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The company operates in the competitive pharmaceutical and medical device industries, targeting the growing markets for allergic rhinitis, nasal viral infections, and pain management.

Comparison to Industry Standards

• The document mentions Alzair, NASAL EASE ALLERGY BLOCKER, and Bentrio Allergy Blocker as predicate devices for the PL-14 product candidate, indicating a similar regulatory pathway.
• The FDA submission and clearance process for Alzair, Nasalese, and Bentrio took 86 and 140 days, respectively, providing a benchmark for Polyrizon's PL-14 product candidate.
• The document references a 2024 Fortune Business Insights report projecting the nasal spray market to reach $49.54 billion by 2030, indicating the potential market size for Polyrizon's products.
• The document references a 2023 Transparency Market Research report projecting the global COVID-19 therapeutics market to reach USD 16.2 billion in 2031, indicating the potential market size for Polyrizon's products.
• The document references a 2023 Global Market Insights report projecting the global therapeutic market for allergic to reach $16 billion by 2032, indicating the potential market size for Polyrizon's products.
• The document references a 2023 Infinium Global Research report projecting the global allergen blocker market will reach $214.5 million in 2030, indicating the potential market size for Polyrizon's products.
• The document references a 2023 report by The Brainy Insights, the global market for intranasal drug delivery is projected to reach $136.46 billion by 2032, indicating the potential market size for Polyrizon's products.
• The document references a 2023 Future Market Insight research, the INCS products market is estimated to reach $11.2 billion by 2033, indicating the potential market size for Polyrizon's products.
• The document references a 2024 Polaris Market Research report, the benzodiazepines drug market is expected to reach $4.2 billion by 2032, indicating the potential market size for Polyrizon's products.
• The document references a 2023 Custom Market Insight report, the global naloxone market is expected to grow to $2.47 billion in 2032, indicating the potential market size for Polyrizon's products.
• The document references a 2022 Vantage Market Research report, the naloxone intranasal spray market is projected to attain a value of $1.4 billion by 2030, indicating the potential market size for Polyrizon's products.
• The document references a 2023 report by Precedence Research, the global pain management drugs market size was estimated at $78.14 billion in 2022 and is projected to hit around $115 billion by 2032, indicating the potential market size for Polyrizon's products.

Related Party Transactions

• The company has entered into a share purchase agreement with Xylo Technologies Ltd., a company where one of Polyrizon's directors serves as Chief Executive Officer.
• The company has entered into a convertible loan agreement with Reuven Srugo Construction Company Ltd., a company owned in part by Raul Srugo, a member of the Srugo family.
• The company has entered into a license agreement with SciSparc, issuing Ordinary Shares and warrants in exchange for exclusive rights to the SCI-160 platform for pain treatment. Oz Adler, a director of Polyrizon, is the Chief Executive Officer of SciSparc.

Stakeholder Impact

• Shareholders: Potential for increased value if product candidates are successful, but risk of dilution from future equity offerings.
• Employees: Potential for job growth and career advancement if the company is successful.
• Customers: Potential for new and improved treatments for allergic rhinitis, nasal viral infections, and pain management.
• Suppliers: Potential for increased business if the company's product candidates are successful.
• Creditors: Repayment of convertible loans from IPO proceeds.

Next Steps

• Complete preclinical development for PL-14, PL-15 and PL-16 product candidates.
• Complete clinical development for PL-14 product candidate.
• Complete in vitro feasibility studies of corticosteroid, benzodiazepine, naloxone for T&T platform technology product candidates.
• Repay the April 2024 CLA and August 2024 CLA.
• Pursue regulatory approvals for product candidates.
• Initiate feasibility clinical trials for PL-15 and PL-16 product candidates (subject to additional financing).
• Initiate pivotal clinical trials for PL-15 and PL-16 product candidates (subject to additional financing).
• Start an initial testing to explore the potential of SCI-160 platform when combined with the T&T technology.

Key Dates

Keywords

nasal spray, hydrogel, biotech, medical device, IPO, C&C, T&T, allergens, viruses, pharmaceutical